

10764922

FILE 'REGISTRY' ENTERED AT 18:57:18 ON 24 AUG 2004
L1 STRUCTURE UPLOADED
L2 5 S L1
L3 167 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 2 S L4 SUB=L3 SAMPLE
L6 38 S L4 SSS FULL SUB=L3

FILE 'CAPLUS' ENTERED AT 19:01:53 ON 24 AUG 2004
L7 110 S L6
L8 2 S L7 AND PATENT/DT
S L7 NOT 526-13-6/REG#

FILE 'REGISTRY' ENTERED AT 19:04:01 ON 24 AUG 2004
L9 1 S 526-13-6/RN


FILE 'CAPLUS' ENTERED AT 19:04:01 ON 24 AUG 2004
L10 86 S L9
L11 24 S L7 NOT L10
L12 23 S L11 NOT L8
L13 STRUCTURE UPLOADED
S L13

FILE 'REGISTRY' ENTERED AT 19:10:07 ON 24 AUG 2004
L14 0 S L13 SUB=L3 SAMPLE

FILE 'CAPLUS' ENTERED AT 19:10:12 ON 24 AUG 2004
L15 0 S L14 SUBSET=L3

FILE 'REGISTRY' ENTERED AT 19:10:24 ON 24 AUG 2004
L16 0 S L13 SUB=L3 SAMPLE
L17 0 S L13 SSS FULL SUB=L3
L18 0 S L13
L19 0 S L13 SSS FULL


=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 14
L4 HAS NO ANSWERS
L4 STR

10764922




Structure attributes must be viewed using STN Express query preparation.

=> d 113

L13 HAS NO ANSWERS

L13 STR



10764922

=> d bib abs hitstr 1-2

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:972072 CAPLUS
 DN 140:27968
 TI Technical method for producing tropenol
 IN Banholzer, Rolf; Bodenbach, Gisela; Mathes, Andreas; Meissner, Helmut; Specht, Peter
 PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DT **Patent**
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101986	A1	20031211	WO 2003-EP5158	20030516
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10224091	A1	20031211	DE 2002-10224091	20020531
	US 2003236409	A1	20031225	US 2003-448493	20030529
	US 6747153	B2	20040608		
	US 2004158069	A1	20040812	US 2004-764922	20040126
PRAI	DE 2002-10224091	A	20020531		
	US 2002-407121P	P	20020830		
	US 2003-448493	A1	20030529		
OS	CASREACT 140:27968; MARPAT 140:27968				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to a novel, tech. applicable production method for preparing tropenol (I), optionally in the form of hydrates or acid addition salts, from tropanetriol ester II [R = C1-4-alkyl, C2-6-alkenyl, C1-4-alkylene-Ph (optionally substituted with OH or C1-4-alkoxy)] via reaction with (R'')₂NCH(OR')₂ (R' = Me, Et; R'' = Me, Et, CH₂Et), an elimination reaction of acetals III and deacylation of esters IV. Thus, tiotropium bromide was prepared from meteloidin [II; R = CMe:CHMe-(E)], via reaction with Me₂NCH(OMe)₂, elimination reaction of acetal III, hydrolysis of ester IV with NaOH in aqueous EtOH, transesterification by I of di(2-thienyl)glycolic acid Me ester, stereoselective epoxidn. with vanadium(V) oxide in DMF, and N-methylation with MeBr.

IT 526-13-6, Meteloidin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with DMF di-Me acetal; tech. method for producing tropenol)

RN 526-13-6 CAPLUS

CN 2-Butenoic acid, 2-methyl-, (1R,3-endo,5S,6S,7R)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:814128 CAPLUS
 DN 137:322727
 TI Isolation of tropane alkaloid multidrug resistance inhibitors from
 Erythroxylum pervillei and their use for treatment of cancer and
 infections
 IN Kinghorn, A. Douglas; Pezzuto, John M.
 PA The Board of Trustees of the University of Illinois, USA
 SO PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002083669	A1	20021024	WO 2002-US11358	20020411	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US 2003092729	A1	20030515	US 2002-119874	20020410	
	EP 1392685	A1	20040303	EP 2002-762037	20020411	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	BR 2002008791	A	20040309	BR 2002-8791	20020411	
PRAI	US 2001-283394P	P	20010412			
	WO 2002-US11358	W	20020411			

GI



AB The methods that utilize compds. derived from Erythroxylum pervillei and which modulate the activity of P-glycoproteins are disclosed. The compds. overcome multidrug resistance and can be used therapeutically to enhance performance of therapeutic drugs, like chemotherapeutic drug and antibiotics. Thus, new compds. pervilleine A, B (I), C, D, E, F and A N-oxide were isolated from Erythroxylum pervillei along with two known tropane alkaloid esters; they were characterized by NMR and tested for bioactivity. Pervilleine B (I) was tested for in vitro cytotoxicity against human cancer cell lines [ED50 = 9.4 µg/mL (BCI); ED50 = 3.1 µg/mL (Lu1); ED50 = 1.3 µg/mL (Col2); ED50 = 0.1 µg/mL (KB-V1+); ED50 = 8.8 µg/mL (KB-V1-); ED50 = 1.0 µg/mL (LNCaP); ED50 = 3.2 µg/mL (SW626)], multidrug resistance [IC50 = 3.8 µM (SKOV3 ovarian adenocarcinoma); IC50 = >10 µM (BSKVLB ovarian adenocarcinoma); IC50 = 0.12 µM (SKVLB)] and the relationship of MDR-reversing activity and physicochem. properties [IC50 = >35 µM (KB-3); IC50 = 15 µM (KB-V); IC50 = 0.17 µM (KB-V, done in the presence of vinblastine)].

IT **104086-63-7**, Tropane-3α,6β,7β-triol 3-phenylacetate
 RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (isolation, NMR, crystal structure and bioactivity of; tropane alkaloid multidrug resistance inhibitors from Erythroxylum pervillei and their


10764922

use for treatment of cancer and infections)

RN 104086-63-7 CAPLUS

CN Benzeneacetic acid, (1R,3-endo,5S,6S,7R)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10764922

=> d 1, 5, 10, 15, 20, 23 bib abs hitstr


L12 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:716925 CAPLUS
DN 140:108110
TI Alkaloids of *Datura ceratocaula*
AU Berkov, Strahil
CS Department of Applied Botany, Institute of Botany, Bulgarian Academy of Sciences, Sofia, 1113, Bulg.
SO Zeitschrift fuer Naturforschung, C: Journal of Biosciences (2003), 58(7/8), 455-458
CODEN: ZNCBDA; ISSN: 0939-5075
PB Verlag der Zeitschrift fuer Naturforschung
DT Journal
LA English
AB Thirty-six alkaloids were identified in the organs of *Datura ceratocaula* by GC/MS. Thirty-three of them have not been previously reported for the species. Furthermore, a new tropane ester was tentatively identified as 3-(3'-formyloxytropoyloxy)tropane on basis of its mass spectral fragmentation. Hyoscyamine was the main alkaloid in the plant organs.
IT **646063-97-0 646063-98-1**
RL BSU (Biological study, unclassified); BIOL (Biological study) (alkaloids of *Datura ceratocaula*)
RN 646063-97-0 CAPLUS
CN 2-Butenoic acid, 2-methyl-, (3-endo)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, (2E)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 646063-98-1 CAPLUS
CN 2-Butenoic acid, 2-methyl-, (3-exo)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, (2E)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:348260 CAPLUS
DN 137:75928
TI New tropane alkaloids from *Erythroxylum moonii*
AU Khattak, Khanzadi Fatima; Atta-ur-Rahman; Choudhary, Mohammad Iqbal; Hemalal, K. D.; Tillekeratne, L. M.
CS H.E.J. Research Institute of Chemistry, University of Karachi, International Center for Chemical Sciences, Karachi, 75270, Pak.
SO Journal of Natural Products (2002), 65(6), 929-931
CODEN: JNPRDF; ISSN: 0163-3864
PB American Chemical Society
DT Journal
LA English
GI




AB Four new tropane alkaloids were isolated from the leaves of *Erythroxylum moonii* and identified as 3 α -isobutyryloxy-7 β -hydroxynortropane (e.g. I), 3 α -hydroxy-7 β -phenylacetoxynortropane, 3 α -cis-cinnamoyloxytropane, and 3 α -hydroxy-6 β -(3'-hydroxy-2'-methyl-3'-phenylpropionyloxy)-7 β -hydroxytropane. Other alkaloids isolated for the first time from *E. moonii* were 3 α -benzoyloxytropane, 3 α -phenylacetoxytropane, 3 α -trans-cinnamoyloxytropane, and 3 α -phenylacetox-6 β ,7 β -dihydroxynortropane. The structures of the new compds. were elucidated by spectroscopic methods.

IT **439791-52-3**, 3 α -Phenylacetox-6 β ,7 β -dihydroxynortropane
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (tropane alkaloids from *Erythroxylum moonii*)

RN 439791-52-3 CAPLUS

CN Benzenecetic acid, (1R,3-endo,5S,6S,7R)-6,7-dihydroxy-8-azabicyclo[3.2.1]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:175556 CAPLUS

DN 112:175556

TI Alkaloids of the genus *Erythroxylum*. Part 10. Alkaloids of *Erythroxylum hypericifolium* leaves

AU Al-Said, Mansour S.; Evans, William C.; Grout, Raymond J.

CS Dep. Pharm. Sci., Univ. Nottingham, Nottingham, NG7 2RD, UK

SO Phytochemistry (1989), 28(11), 3211-15

CODEN: PYTCAS; ISSN: 0031-9422

DT Journal

LA English

AB Fifteen alkaloids were characterized from the leaves of *E. hypericifolium*; the majority are esters of cinnamic and benzoic acids.

3 α -Cinnamoyloxytrop-6 β -ol is the main base. New alkaloids

reported are 3 β -cinnamoyloxytropane, 3 α ,6 β -

dicinnamoyloxytropane, 3-cinnamoyloxynortrop-6-ol, 6 β -acetox-

3 α -cinnamoyloxytropane and, tentatively, 6-phenylacetoxytrop-3-ol.

Two mixed cinnamate dimers were also found. Some syntheses are reported

and the chemotaxonomic implications of the results are discussed.

IT **117005-30-8**


RL: BOC (Biological occurrence); BSU (Biological study, unclassified);

BIOL (Biological study); OCCU (Occurrence)


(of *Erythroxylum hypericifolium*)

RN 117005-30-8 CAPLUS

CN 2-Propenoic acid, 3-phenyl-, 6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)




L12 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1979:39083 CAPLUS
 DN 90:39083
 TI Synthesis of betalains
 AU Buchi, George; Fliri, Hans; Shapiro, Rafael
 CS Dep. Chem., Massachusetts Inst. Technol., Cambridge, MA, USA
 SO Journal of Organic Chemistry (1978), 43(25), 4765-9
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 GI




AB N-Benzyl norteloidinone (I, R = PhCH₂, R₁R₂ = O, R₃ = R₄ = H), prepared by Robinson-Schöpf synthesis, was converted to the ortho ester I (R = PhCH₂ with HC(OMe)₃). Catalytic debenzoylation of I (R₁R₂ = O, R₃R₄ = MeOCH) followed by addition of allylmagnesium bromide gave the carbinol, which was transformed to the I (R = PhCO₂, R₁ = OH, R₂ = H₂C:CHCH₂, R₃R₄ = MeOCH) with benzoyl peroxide. Acetylation of the tertiary carbinol was followed by hydrolysis of the ortho ester to the diol. Consecutive oxidns. of the diol to the α-diketone with dimethyl sulfide-N-chlorosuccinimide, and of the olefin to the aldehyde with ozone, gave the diketo aldehyde II. Treatment of II with lead Ph(OAc)₄ in MeOH-C₆H₆ gave a di-Me ester which, upon chromatog. over silica gel, lost both AcOH and BzOH to give di-Me betalamate, characterized by a crystalline semicarbazone (III) of unknown stereochem. Conversion of III to indicaxanthin and betanidin was accomplished using known procedures.

IT **63321-97-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 63321-97-1 CAPLUS
 CN 8-Azabicyclo[3.2.1]octane-3,6,7-triol, 8-(benzoyloxy)-3-(2-propenyl)-, 3-acetate, (3-endo,6-exo,7-exo)- (9CI) (CA INDEX NAME)




L12 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:549747 CAPLUS
 DN 77:149747
 TI Biosynthesis of the isovaleryl and senecieryl moieties of tropane alkaloids
 AU Achari, R. G.; Court, W. E.; Newcombe, F.
 CS Sch. Org. Chem., Univ. Bradford, Bradford/Yorkshire, UK
 SO Planta Medica (1972), 22(1), 38-41
 CODEN: PLMEAA; ISSN: 0032-0943
 DT Journal
 LA English

- AB Incorporation of radioactivity from L-leucine-U-14C and L-valine-U-14C into 8 alkaloids extracted from *Datura sanguinea* and *D. stramonium* plants indicated that both amino acids can act as precursors to several isovaleryl and senecieryl moieties of the tropane alkaloids, including 3-senecieryl-, 3-isovaleryl-, 3,6-disenecieryl-, and 3,6-diisovaleryl esters of oxytropine; 3,6-disenecieryl- and 3,6-divaleryl esters of oxytropine-7-ol, and 3-senecieryl and 3-isovaleryl esters of oxytropine-6,7-diol.
- IT **38753-89-8**
 RL: BIOL (Biological study)
 (formation of isovaleryl moiety of)
- RN 38753-89-8 CAPLUS
- CN Butanoic acid, 3-methyl-, 6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)




- IT **38753-88-7**
 RL: BIOL (Biological study)
 (formation of senecieryl moiety of)
- RN 38753-88-7 CAPLUS
- CN 2-Butenoic acid, 3-methyl-, 6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)



- L12 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1955:20108 CAPLUS
- DN 49:20108
- OREF 49:3987g-i,3988a-e
- TI The synthesis of dihydrometeloidine and related compounds
- AU Sheehan, John C.; Bissell, Eugene R.
- CS Massachusetts Inst. of Technol., Cambridge
- SO Journal of Organic Chemistry (1954), 19, 270-6
- JOCEAH; ISSN: 0022-3263
- DT Journal
- LA Unavailable
- AB Dihydrometeloidine (I), structurally related to meteloidine, a natural oxygenated tropane alkaloid, has been synthesized. Teloidinone (II) (3.4 g.) and 4.2 g. p-MeC6H4SO3H.H2O in 40 cc. BzH are kept 48 hrs. at 20°, ether is added, the precipitate mixed with 50 cc. N NaOH, and extracted with C6H6, giving 89% benzylideneteloidinone (III), prismatic needles, m. 150-1° [HBr salt, needles, m. 215-16° (decomposition); p-toluenesulfonate, m. 202-3° (decomposition)]. Hydrogenation of 1.95 g. III in 200 cc. 70% EtOH with W-4 Raney Ni at 20° 3-6 hrs. gives 89.5% benzylideneteloidine (IV), needles, m. 163-5° after sublimation at 120°/0.05 mm. [picrate, yellow needles, m. 189-90° (decomposition); HBr salt, m. 236-7° (decomposition)]. Adding Na to 260 mg. IV in 25 cc. liquid NH3, until the blue color persists 1 hr., decomposing the mixture with 500 mg. NH4Cl, and evaporating the NH3 give 50 mg. teloidine, m. 166-8° (decomposition). Treating 1 g. IV with 6 cc. α-methylbutyric anhydride in 6 cc. C5H5N 24 hrs., concentrating the mixture in vacuo, taking up the residue in 25 cc. N HCl, extracting with ether, making the aqueous solution alkaline with 6 cc. 6N NaOH, and again extracting with ether give 61% benzylidene-α-methylbutyrylteloidine (V).HBr, platelets, m. 237.5-8.5° (decomposition) (picrate, yellow needles, m. 161-2°). Hydrogenating 500 mg. V in 10 cc. AcOH with 200 mg. prerduced 30% Pd-C at 20° gives 95.5% I, needles, m. 96-7° [HBr salt, platelets, m. 216-17° (decomposition)]. Treating 1 g. IV in 6 cc C5H5N with 4 cc. Ac2O 24 hrs. at 20° gives 80% benzylideneacetylteloidine (VI), m. 110.5-11.5° [HBr salt, needles, m. 276-7° (decomposition)]. Hydrogenolysis of 500 mg. VI gives 85% acetylteloidine (VII), m.


178.5-9.5° (decomposition) [HBr salt, m. 207-8° (decomposition)]. Acetylation of teloidine or VII with Ac 2O-C₅H₅N at 20° gives 65% teloidine triacetate, m. 84.5-5.5°. Treating 260 mg. IV in 10 cc. ether with 220 mg. Ph₂C:CO 20 hrs. at 20°, evaporating the mixture, and neutralizing the residue with HBr give 83% benzylidenediphenylacetyl teloidine-HBr, platelets, m. 256-7° (decomposition) [methiodide, m. 205-6° (decomposition)]. Refluxing 3.4 g. II and 4.2 g. p-MeC₆H₄SO₃H.H₂O in 500 cc. Me₂CO 24 hrs., adding 100 cc. 0.5N NaOH, evaporating the Me₂CO, and extracting the residual solution with ether give 82.3% isopropylideneteloidinone (VIII), needles, m. 89-90° [picrate, yellow needles, m. 214-15°; HBr salt, m. 241.5-2.5°; methiodide, prisms, m. 227-8° (decomposition)]. Hydrogenation of VIII gives 94.3% isopropylideneteloidine (IX), m. 131-3° [HBr salt, needles, m. 195.5-6.5°]. Heating 215 mg. IX with 10 cc. N HCl 15 min. gives teloidine-HCl, m. 307-8° (decomposition). Isopropylideneacetyl teloidine, prepared in 77% yield in the same way as VI, prismatic needles, m. 73.5-5° [picrate, yellow needles, m. 213-14°; HCl salt, prisms, m. 289-90° (decomposition); HBr salt, needles, m. 295-6° (decomposition)]. Isopropylidenediphenylacetyl teloidine-HBr, m. 165-6.5°; methiodide, needles, m. 211-12°. Heating 215 mg. IX with 785 mg. BzCl 2 hrs. gives 38% isopropylidenebenzoyl teloidine-HBr, m. 264-5° (decomposition). Refluxing 3.4 g. II and 4.2 g. p-MeC₆H₄SO₃H.H₂O in 500 cc. Me₂CO, adding 100 cc. 0.5N NaOH, distilling off the Me₂CO in vacuo, concentrating the aqueous solution, treating the residue with 1.5 g. NaBH₄ at 20°, extracting the mixture 24 hrs. with CH₂Cl₂, and subliming the residue of the CH₂Cl₂ extract give 50% isopropylidenepseudoteloidine (X), prisms, m. 121-3° [HCl salt, m. 250-1°; HBr salt, prisms, m. 249-50° (decomposition)]. Hydrolysis of 215 mg. X 15 min. with 10 cc. N HCl gives 87% pseudoteloidine-HCl, m. 265-6° (decomposition). Isopropylideneacetyl pseudoteloidine, prepared in 83.7% yield similarly to VI, m. 125-6.5°.

IT 4074-15-1, Meteloidine, dihydro-
(and derivs.)
RN 4074-15-1 CAPLUS
CN 1αH,5αH-Tropane-3α,6β,7β-triol,
3-(2-methylbutyrate) (8CI) (CA INDEX NAME)



IT 109655-83-6, Teloidine, 3-acetate
(preparation of)
RN 109655-83-6 CAPLUS
CN Teloidine, 3-acetate (6CI) (CA INDEX NAME)

Relative stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 18:56:47 ON 24 AUG 2004)

FILE 'REGISTRY' ENTERED AT 18:57:18 ON 24 AUG 2004


L1 STRUCTURE UPLOADED
L2 5 S L1
L3 167 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 2 S L4 SUB=L3 SAMPLE
L6 38 S L4 SSS FULL SUB=L3

FILE 'REGISTRY' ENTERED AT 19:04:01 ON 24 AUG 2004

FILE 'CAPLUS' ENTERED AT 19:04:01 ON 24 AUG 2004

```
=> d 2,6,11,16,21 bib abs hitstr
```

Relative stereochemistry.



LI2 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:841082 CAPLUS
 DN 136:131532
 TI Modulation of the Multidrug-Resistance Phenotype by New Tropane Alkaloid
 Aromatic Esters from *Erythroxylum pervillei*
 AU Silva, Gloria L.; Cui, Baoliang; Chavez, Daniel; You, Min; Chai,
 Hee-Byung; Rasoanaivo, Philippe; Lynn, Sean M.; O'Neill, Melanie J.;
 Lewis, Jane A.; Besterman, Jeffrey M.; Monks, Anne; Farnsworth, Norman R.;
 Cordell, Geoffrey A.; Pezzuto, John M.; Kinghorn, A. Douglas
 CS Program for Collaborative Research in the Pharmaceutical Sciences and
 Department of Medicinal Chemistry and Pharmacognosy College of Pharmacy,
 University of Illinois at Chicago, Chicago, IL, 60612, USA
 SO Journal of Natural Products (2001) 64(12) 1514-1520

CODEN: JNPRDF; ISSN: 0163-3864

PB American Chemical Society

DT Journal

LA English

AB Nine tropane alkaloid aromatic esters (1-9) were isolated from the roots of *Erythroxylum pervillei* by following their potential to reverse multidrug-resistance with vinblastine-resistant oral epidermoid carcinoma (KB-V1) cells. All isolates, including seven new structures (3-9), were evaluated against a panel of human cancer cell lines, and it was found that alkaloids 3 and 5-9 showed the greatest activity with KB-V1 cells assessed in the presence of vinblastine, suggesting that these new compounds are potent modulators of P-glycoprotein. Confirmatory results were obtained with human ovarian adenocarcinoma (SKVLB) cells evaluated in the presence of adriamycin and synergistic studies performed with several cell lines from the NCI tumor panel. The structures of the new compounds were determined using spectroscopic techniques. Single-crystal X-ray anal. was performed on the monoester, tropane-3 α ,6 β ,7 β -triol 3-phenylacetate (1).


IT 104086-63-7, Tropane-3 α ,6 β ,7 β -triol 3-phenylacetate

RL: NPO (Natural product occurrence); PAC (Pharmacological activity); BIOL (Biological study); OCCU (Occurrence)
(modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from *Erythroxylum pervillei*)

RN 104086-63-7 CAPLUS

CN Benzeneacetic acid, (1R,3-endo,5S,6S,7R)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1989:404229 CAPLUS

DN 111:4229

TI Alkaloids of the genus *Erythroxylum*. Part 9. Alkaloids of *Erythroxylum hypericifolium* stem bark

AU Al-Said, Mansour S.; Evans, William C.; Grout, Raymond J.

CS Dep. Pharm. Sci., Univ. Nottingham, Nottingham, NG7 2RD, UK

SO *Phytochemistry* (1989); 28(2), 671-3

CODEN: PYTCAS; ISSN: 0031-9422

DT Journal

LA English

AB Thirteen bases were characterized from the stem bark of *E. hypericifolium*; hygrine is the principal component. As in the root bark esters of phenylacetic acid predominate; other alkaloids involve acetic, benzoic, and trimethoxycinnamic acids. Alkaloids reported for the first time are 3 α -phenylacetoxynortropan-6 β -ol, 6 β -acetoxo-3 α -benzoyloxytropane, and 3-acetoxo-6-phenylacetoxytropane.

IT 104086-63-7


RL: BIOL (Biological study)


(from *Erythroxylum hypericifolium* stem bark)

RN 104086-63-7 CAPLUS


CN Benzeneacetic acid, (1R,3-endo,5S,6S,7R)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





AB	Betalamic acid dimethyl ester (I) was prepared from N-benzyl-norteloidinone (II) via the carbinol III and aldehyde IV in 9 steps.
IT	63321-97-1P
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
	(preparation and oxidation of)
RN	63321-97-1 CAPLUS
CN	8-Azabicyclo[3.2.1]octane-3,6,7-triol, 8-(benzoyloxy)-3-(2-propenyl)-, 3-acetate, (3-endo,6-exo,7-exo)- (9CI) (CA INDEX NAME)



```
L12 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS ON STN
AN 1968:484182 CAPLUS
DN 69:84182
TI Alkaloid production in Datura hybrids
AU Lubis, I.
CS Lembaga Biol. Nas., Bogor, Indonesia
SO Annales Bogorieneses (1967), 4(3), 163-90
CODEN: ABOGAT; ISSN: 0517-8452
DT Journal
LA English
AB Alkaloid contents of the roots of Datura hybrid plants of 6 generations, produced by crossing D. ferox and D. stramonium, were determined F-1 generation plants contained hycocyamine (I) 350, hycoscine (II) 160, 3 $\alpha$ -tigloyloxytropene (III) 85, meteloidine (IV) 190, 7-hydroxy-3,6-ditigloyloxytropene (V) 400, 3,6-ditigloyloxytropene (VI) 60 mg./kg. of roots, and small amts. of tropene and an unidentified alkaloid. F-5 generation plants contained I 155, II 600, III 300, IV 355, V 200, and VI 77 mg./kg. of roots. All 6 alkaloids were detected in the roots of the
```

F2-F5 generation plants, but only I and II were found in the roots of F-6 plants. Unlike the case of the aerial parts of the hybrid plants, where the alkaloid characteristic of the parent *D. ferox* (high content of II) was dominant, the roots contained a high proportion of I up to the F-4 generation, a characteristic feature of *D. stramonium*. This difference was due to the inheritance of another independent genetic factor, namely the epoxidizing ability of the aerial parts, which is responsible for the formation of II from I. Variation in the amts. of III, IV, and V in the roots up to the F-5 generation indicated a tendency toward adoption of *D. ferox* characteristics.

IT **21631-92-5**

RL: BIOL (Biological study)
(in *Datura ferox* and stramonium)

RN 21631-92-5 CAPLUS

CN 1 α H, 5 α H-Tropane-3 β , 6 β , 7 β -triol,
3-(2-methylcrotonate), (E)- (8CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

